Remove Stent Remove Stents Remove Thrombosis
article thumbnail

Philips launches Duo Venous Stent System for Treatment of Symptomatic Venous Outflow Obstruction

DAIC

and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. Duo Hybrid has a distinct integrated design that combines multiple zones of differing mechanical properties into a single stent [3].

Stents 105
article thumbnail

Risk factors, prevention, and therapy of intraluminal stent thrombosis in frozen elephant trunk prostheses—what we know so far

Frontiers in Cardiovascular Medicine

In this phenomenon, a thrombus forms within the lumen of the stent graft component of the frozen elephant trunk prosthesis and puts the patient at risk for downstream embolization with visceral or lower limb ischemia. The long-term efficiency of these prophylactic and therapeutic measures has yet to be proven.

Stents 59
article thumbnail

SMT Publishes Trial Results for Supraflex Cruz Stent

DAIC

Smits and a distinguished team of international researchers, the trial compares the performance of SMT's biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the biodegradable-polymer Ultimaster Tansei * stent in patients with high bleeding risk (HBR) undergoing abbreviated dual antiplatelet therapy (DAPT).

Stents 52
article thumbnail

Clinical outcomes and aortic remodeling after Castor single-branched stent-graft implantation for type B aortic dissections involving left subclavian artery

Frontiers in Cardiovascular Medicine

BackgroundThe left subclavian artery (LSA) can be intentionally covered by a stent graft to acquire adequate landing zones for a proximal entry tear near the LSA during thoracic endovascular aortic repair (TEVAR). The Castor single-branched stent graft is designed to treat type B aortic dissection (TBAD) to retain the LSA during TEVAR.

Aortic 52
article thumbnail

Percutaneous Coronary Interventions Using a Ridaforolimus?Eluting Stent in Patients at High Bleeding Risk

Journal of the American Heart Association

Drug‐eluting stents have been shown to be superior to bare‐metal stents in patients with HBR, even when patients were given abbreviated periods of dual antiplatelet therapy (DAPT). Short DAPT has not been evaluated with the EluNIR ridaforolimus‐eluting stent. presented with acute coronary syndrome; 33.7%

Stents 40
article thumbnail

Bioresorbable vascular scaffolds versus conventional drug-eluting stents across time: a meta-analysis of randomised controlled trials

Open Heart

Background Bioresorbable vascular scaffolds (BVS) were designed to reduce the rate of late adverse events observed in conventional drug-eluting stents (DES) by dissolving once they have restored lasting patency.

Stent 52
article thumbnail

Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study

Cardiovascular Diabetology

Subjects with type 2 diabetes (T2D) have a higher risk of in-stent restenosis and stent thrombosis. The activation of the glucagon-like peptide-1 receptor (GLP-1R) has been suggested to induce several effects.